Gkrozou F, Pappa C, Tsonis O, Dimitriou E, Paschopoulos M
Department of Obstetrics and Gynaecology, University Hospitals of Birmingham, UK.
Department of Obstetrics and Gynaecology, General Hospital "Hatzikosta", Ioannina, Greece.
Eur J Obstet Gynecol Reprod Biol. 2021 May;260:99-104. doi: 10.1016/j.ejogrb.2021.03.008. Epub 2021 Mar 15.
Ovarian cancer is a leading cause of female mortality worldwide. Although novel approaches on this disease have been developed, overall survival rates remain moderate due to the lack of scientific evidence promoting screening at early stages of the disease. A number of biomarkers have been suggested as predictive for this type of cancer. The role of relaxin in endometrial cancer is well documented but the scientific evidence is lacking with regards to ovarian cancer. We studied patients with ovarian cancer, benign ovarian cyst and healthy patients too. The levels of relaxin have been found to be an adequate diagnostic biomarker for ovarian cancer. We also presented the different range of Ca125, HE4 and ROMA in these three groups. Randomised control trials need to be conducted though, in order to elucidate the true role of relaxin in these cases.
卵巢癌是全球女性死亡的主要原因。尽管针对这种疾病已开发出新颖的方法，但由于缺乏促进疾病早期筛查的科学证据，总体生存率仍然一般。一些生物标志物已被认为可预测此类癌症。松弛素在子宫内膜癌中的作用已有充分记录，但在卵巢癌方面缺乏科学证据。我们也研究了卵巢癌患者、卵巢良性囊肿患者和健康患者。已发现松弛素水平是卵巢癌的一种充分的诊断生物标志物。我们还展示了这三组中Ca125、HE4和ROMA的不同范围。不过，需要进行随机对照试验，以阐明松弛素在这些病例中的真正作用。
